scholarly journals Symptomatology and quality of life in patients with rate-responsive pacemakers: A double-blind, randomized, crossover study

1989 ◽  
Vol 12 (9) ◽  
pp. 505-512 ◽  
Author(s):  
C.-P. Lau ◽  
J. Rushby ◽  
M. Leigh-Jones ◽  
C. Y. F. Tam ◽  
J. Poloniecki ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crossover Study ◽  
Double Blind ◽  
Randomized Crossover Study ◽  
Rate Responsive

Randomized, crossover study evaluating patient preference and the impact on quality of life of urisheaths vs absorbent products in incontinent men

2010 ◽  
Vol 108 (2) ◽  
pp. 241-247 ◽  
Author(s):  
Emmanuel Chartier-Kastler ◽  
Philippe Ballanger ◽  
Jacques Petit ◽  
Marc Fourmarier ◽  
Stéphane Bart ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Crossover Study ◽  
Patient Preference ◽  
The Impact ◽  
Randomized Crossover Study

scholarly journals Botulinum Toxin in Restless Legs Syndrome—A Randomized Double-Blind Placebo-Controlled Crossover Study

Toxins ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 401 ◽  
Author(s):  
Shivam Mittal ◽  
Duarte Machado ◽  
Diana Richardson ◽  
Divyanshu Dubey ◽  
Bahman Jabbari
Keyword(s):  
Quality Of Life ◽  
Crossover Study ◽  
Pain Score ◽  
Restless Legs Syndrome ◽  
Biceps Femoris ◽  
Life Questionnaire ◽  
Double Blind ◽  
Restless Legs ◽  
Global Impression Of Change

Background: Restless Legs Syndrome (RLS) is a common movement disorder with an estimated prevalence of up to 12%. Previous small studies with onabotulinumtoxin A (OnaA) for RLS have shown inconsistent results. Methods: Twenty-four patients with an International RLS score (IRLS) of >11 (moderate-severe) were enrolled in this blinded, placebo-controlled crossover study. Twenty-one patients completed the evaluations at 4, 6, and 8 weeks after each injection. One-hundred units of Incobotulinumtoxin A (IncoA) or normal saline were injected into tibialis anterior, gastrocnemius, and biceps femoris muscles each side. Results: Improvement from a severe (IRLS >21) to a mild/moderate (IRLS ≤20) score was significant at four weeks (p = 0.0036) and six weeks (p = 0.0325) following IncoA administration compared to placebo. Additionally, there was significant improvement in pain score at six weeks as measured by Visual Analogue Scale (p = 0.04) and the Johns Hopkins Quality of Life Questionnaire (p = 0.01) in the IncoA group. Definite or marked improvement on Patient Global Impression of Change was seen in 7 out of 21 patients in the IncoA group vs. 1 out of 21 patients in the placebo group at 4 weeks (p = 0.012). Conclusion: IncoA injection lead to a reduction in severity of RLS symptoms, pain score, and quality of life, without any adverse effects.

Sign in / Sign up

Export Citation Format

Share Document